The Relationship Between Heart Function and Metabolism in HFpEF Patients

NCT ID: NCT05053256

Last Updated: 2022-08-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-01

Study Completion Date

2023-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

HFpEF has gradually become the most common form of heart failure. Studies have found that metabolic abnormalities and chronic inflammation ultimately lead to HFpEF by promoting heart remodeling. However, there are few relevant studies and the mechanism is still unclear.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

However, heart failure with preserved ejection fraction is difficult to diagnose and treat due to its unknown pathogenesis and poor prognosis. Ventricular diastolic dysfunction and retention of left ventricular ejection fraction are important pathological features of Heart failure with preserved ejection fraction. Currently, it is widely believed to be a clinical syndrome associated with old age, women, obesity, diabetes, hypertension, atrial fibrillation, coronary heart disease, atherosclerosis, etc. However, the specific mechanism of heart failure with preserved ejection fraction caused by the above-mentioned complications is unknown. In conclusion, the investigators intend to explore the pathogenesis of heart failure with preserved ejection fraction by observing the changes of heart and body metabolism in patients with heart failure with preserved ejection fraction, and provide a basis for the diagnosis and treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure With Preserved Ejection Fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HFpEF

Heart failure with preserved ejection fraction

No interventions assigned to this group

HFrEF

Heart failure with reduced ejection fraction

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult aged ≥ 18 years old
* Patients diagnosed with HFpEF;

Diagnostic criteria including:

1. LVEF 50% or higher;
2. BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL;
3. Presence of symptoms and/or signs of heart failure;
4. At least one additional criteria: relevant structure heart disease or diastolic dysfunction

Exclusion Criteria

* Severe liver failure;
* Other causes of shortness of breath, such as severe pulmonary disease or severe ● chronic obstructive pulmonary disease;
* Primary pulmonary hypertension.
* Severe left valvular heart disease.
* Long-term bedridden or unable to move autonomously
* Age \< 18
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chongqing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dongying Zhang

Clinical Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dongying Zhang, doctor

Role: STUDY_DIRECTOR

First Affiliated Hospital of Chongqing Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital of Chongqing Medical University

Chongqing, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dongying Zhang, doctor

Role: CONTACT

+8613608398395

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dongying Zhang, doctor

Role: primary

+8613608398395

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-08-29

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Serum IGF1 on Female HFpEF Patients
NCT07015554 ENROLLING_BY_INVITATION
CTO-PCI in Heart Failure Patients
NCT05632653 NOT_YET_RECRUITING NA